Cynata Therapeutics Limited (CYYNF PINK) stock market data APIs
$0.2224
0(0%)
as of May 4, 2026
Try our APIs with
free plan!
Cynata Therapeutics Limited Financial Data Overview
Price chart is built with
Anychart
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Prev. Close
0.2224
Open
0.2224
High
0.2224
Low
0.2224
52 wk Range
0.08-0.2221
Market Cap
52 739 K
Shares Outstanding
237 M
Revenue
1 687 K
EPS
-0.0075
Beta
1.079
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cynata Therapeutics Limited data using free add-ons & libraries
Get Cynata Therapeutics Limited Fundamental Data
Cynata Therapeutics Limited Fundamental data includes:
- Net Revenue: 1 687 K
- EBITDA: -8 346 995
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Cynata Therapeutics Limited Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cynata Therapeutics Limited News
New
ASX Opportunities: Aroa Biosurgery And 2 Other Promising Penny Stocks
The Australian market is experiencing a challenging period, with a significant downturn influenced by global market pressures and recent tech selloffs. Despite the turbulence, investors often seek opp...
3 ASX Penny Stocks With Market Caps Under A$200M To Consider
The Australian market has been buzzing with activity, reflecting a festive spirit reminiscent of October's highs, despite ongoing tech jitters and fluctuating oil prices. For investors interested in s...
Get Cynata Therapeutics Limited fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
